Literature DB >> 25120816

Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.

Xuan J Wang1, Annette Kim1, Shaoying Li1.   

Abstract

Hairy cell leukemia (HCL) is usually diagnosed by morphology and flow cytometry studies. However, it is challenging sometimes to distinguish HCL from its mimics. Recently, the BRAF V600E mutation has been described as a disease-defining molecular marker for HCL which is present in nearly all cases of HCL but virtually absent in mimics of HCL. In this study, we investigated the possibility of using immunohistochemical detection of the BRAF V600E mutant protein to differentiate HCL from its mimics. A total of twenty-eight FFPE tissue specimens were studied, including HCL (n=12), HCL variant (HCL-v, n=3), splenic marginal zone lymphoma (SMZL, n=6), and other marginal zone lymphomas (MZL, n=7). Immunohistochemical studies were performed using a mouse monoclonal antibody (clone VE1, Spring Bioscience, CA) specific for BRAF V600E mutation. Molecularly confirmed BRAF V600E mutation positive and negative cases were used as the positive and negative controls respectively. All 12 cases of HCL showed cytoplasmic BRAF V600E protein expression in leukemia cells by immunohistochemical study regardless of tumor burden, whereas all cases of HCL mimics including HCL-v, SMZL, and MZL were negative for BRAF V600E protein. Using this BRAF V600E mutation specific antibody, this immunohistochemical study has 100% sensitivity and 100% specificity for the diagnosis of HCL in our cohort. In conclusion, immunohistochemical detection of the BRAF V600E mutant protein is highly sensitive and specific for the diagnosis of HCL. Compared to PCR or sequencing-based methodologies, immunohistochemistry is a relatively rapid and inexpensive alternative for the differential diagnosis between HCL and its mimics.

Entities:  

Keywords:  BRAF V600E; hairy cell leukemia; immunohistochemistry

Mesh:

Substances:

Year:  2014        PMID: 25120816      PMCID: PMC4129051     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

1.  Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Authors:  Liqiang Xi; Evgeny Arons; Winnifred Navarro; Katherine R Calvo; Maryalice Stetler-Stevenson; Mark Raffeld; Robert J Kreitman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

2.  Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia.

Authors:  Mindaugas Andrulis; Roland Penzel; Wilko Weichert; Andreas von Deimling; David Capper
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

3.  Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.

Authors:  David Capper; Anna Sophie Berghoff; Manuel Magerle; Aysegül Ilhan; Adelheid Wöhrer; Monika Hackl; Josef Pichler; Stefan Pusch; Jochen Meyer; Antje Habel; Peter Petzelbauer; Peter Birner; Andreas von Deimling; Matthias Preusser
Journal:  Acta Neuropathol       Date:  2011-10-20       Impact factor: 17.088

4.  Distinct sets of genetic alterations in melanoma.

Authors:  John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

6.  High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies.

Authors:  Elaine M Boyd; Anthony J Bench; Mars B van 't Veer; Penny Wright; David M Bloxham; George A Follows; Mike A Scott
Journal:  Br J Haematol       Date:  2011-09-13       Impact factor: 6.998

7.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

8.  Alternative BRAF mutations in BRAF V600E-negative hairy cell leukaemias.

Authors:  Sebastian Tschernitz; Lucia Flossbach; Margrit Bonengel; Sabine Roth; Andreas Rosenwald; Eva Geissinger
Journal:  Br J Haematol       Date:  2014-01-16       Impact factor: 6.998

9.  Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.

Authors:  Hans Bösmüller; Anna Fischer; Deborah L Pham; Tanja Fehm; David Capper; Andreas von Deimling; Irina Bonzheim; Annette Staebler; Falko Fend
Journal:  Hum Pathol       Date:  2012-10-22       Impact factor: 3.466

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  1 in total

1.  Upregulation of RSPO2-GPR48/LGR4 signaling in papillary thyroid carcinoma contributes to tumor progression.

Authors:  Yea Eun Kang; Jin-Man Kim; Koon Soon Kim; Joon Young Chang; Mingyu Jung; Junguee Lee; Shinae Yi; Hyeon Woo Kim; Jung Tae Kim; Kyungmin Lee; Min Jeong Choi; Seul Ki Kang; Seong Eun Lee; Hyon-Seung Yi; Bon Seok Koo; Minho Shong
Journal:  Oncotarget       Date:  2017-11-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.